2031년까지 글로벌 및 러시아 암 치료제 시장 전망

Global & Russia Cancer Therapeutics Market to 2031

상품코드Romania Cancer Therapeutics Market.pdf
발행기관Business Market Insights
발행일2025.05.26
페이지 수100 Pages
포맷PDF
커버리지Country

₩3,600,000 – ₩6,600,000

보고서 요약(국문)

러시아의 암 치료제 시장은 암 발병률 증가, 의료 인프라 개선, 조기 진단 및 치료에 대한 인식 제고에 힘입어 지속적인 성장을 보이고 있습니다. GLOBOCAN 데이터에 따르면, 러시아에서는 2023년에 60만 건 이상의 새로운 암 환자가 발생했으며, 약 30만 명이 암 관련 질환으로 사망했습니다. 가장 흔한 암은 폐암, 유방암, 대장암, 전립선암이며, 특히 흡연율이 높은 러시아에서는 폐암이 주요 문제로 대두되고 있습니다. 고령화, 흡연 및 음주와 같은 생활 습관 위험 요인, 환경 오염 등도 암 부담 증가에 기여하고 있습니다. 2022년에는 약 64만 건의 새로운 암 환자가 보고되었으며, 대장암과 유방암이 가장 많이 진단되었습니다. 같은 해 암 관련 사망자는 약 31만 명에 달했으며, 이 중 약 83,693건이 대장암으로 전체 사망자의 13.2%를 차지했습니다. 이는 효과적인 암 치료법에 대한 상당한 수요를 보여줍니다.

시장은 첨단 치료법의 접근성 향상으로 더욱 활성화되고 있습니다. 표적 치료, 면역 치료, 맞춤형 의학이 점차 보편화되고 있으며, 키트루다(펨브롤리주맙)와 옵디보(니볼루맙)와 같은 면역항암제가 그 선두에 서 있습니다. 또한, 바이오시밀러의 사용 증가로 고가의 생물학적 제제에 대한 보다 저렴한 대안이 제공되어 치료 접근성이 확대되고 있습니다. 허셉틴과 리툭산과 같은 약물의 바이오시밀러는 러시아에서 점점 더 인기를 얻고 있습니다. 로슈, 화이자 등 주요 글로벌 제약 회사와의 파트너십은 혁신적인 암 치료법 도입을 더욱 뒷받침하여 러시아 환자들에게 더 넓은 치료 선택권을 제공하고 있습니다.

보고서 요약(영어 원문)

The cancer therapeutics market in Russia has been experiencing consistent growth, fueled by a rising incidence of cancer, enhancements in healthcare infrastructure, and increased awareness around early diagnosis and treatment. According to GLOBOCAN data, Russia saw over 600,000 new cancer cases in 2023, alongside approximately 300,000 cancer-related deaths. The most common cancers include lung, breast, colorectal, and prostate cancers, with lung cancer posing a major challenge due to high smoking prevalence. Factors such as an aging population, lifestyle risks like smoking and alcohol use, and environmental pollution contribute to the growing cancer burden. In 2022, around 640,000 new cancer cases were reported, with colorectal and breast cancers being the most frequently diagnosed. That year, cancer-related deaths reached roughly 310,000, including about 83,693 new colorectal cancer cases, which accounted for 13.2% of all registered cases—highlighting the substantial need for effective cancer therapies.

The market is also benefiting from the increasing availability of advanced treatments. Targeted therapies, immunotherapies, and personalized medicine are becoming more accessible, with immuno-oncology drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) leading the way. Additionally, the growing use of biosimilars offers more affordable alternatives to costly biologics, expanding access to treatment. Biosimilars for medications such as Herceptin and Rituxan are becoming increasingly popular in Russia. Partnerships with major global pharmaceutical companies, including Roche and Pfizer, have further supported the introduction of innovative cancer therapies, broadening treatment options for patients in the country.

상세 목차

TABLE OF CONTENTS

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation:

4. Russia Cancer Therapeutics Market Landscape

4.1 Overview

4.2 Ecosystem Analysis

4.2.1 List of Vendors in the Value Chain

5. Cancer Therapeutics Market Key Market Dynamics

5.1 Cancer Therapeutics Market – Key Market Dynamics

5.2 Market Drivers

5.3 Market Restraints

5.4 Market Opportunities

5.5 Future Trends

5.6 Impact of Drivers and Restraints

6. Russia Cancer Therapeutics Market – Analysis

6.1 Russia Cancer Therapeutics Market Revenue (US$ Million), 2021–2031

6.2 Russia Cancer Therapeutics Market Revenue and Forecast Analysis

7. Russia Cancer Therapeutics Market Analysis – by Therapy Types

7.1 Russia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types

8. Russia Cancer Therapeutics Market Analysis – by Indications

8.1 Russia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications

9. Russia Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Russia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players

10.1 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.2 Partnerships and Collaborations

11.2 Other Developments

12. Company Profiles

12.1 Bristol-Myers Squibb Co

12.1. 1 Key Facts

12.1. 2 Business Description

12.1. 3 Products and Services

12.1. 4 Financial Overview

12.1. 5 SWOT Analysis

12.1. 6 Key Developments

12.2 AbbVie Inc

12.2. 1 Key Facts

12.2. 2 Business Description

12.2. 3 Products and Services

12.2. 4 Financial Overview

12.2. 5 SWOT Analysis

12.2. 6 Key Developments

12.3 Johnson & Johnson

12.3. 1 Key Facts

12.3. 2 Business Description

12.3. 3 Products and Services

12.3. 4 Financial Overview

12.3. 5 SWOT Analysis

12.3. 6 Key Developments

12.4 F. Hoffmann-La Roche Ltd

12.4. 1 Key Facts

12.4. 2 Business Description

12.4. 3 Products and Services

12.4. 4 Financial Overview

12.4. 5 SWOT Analysis

12.4. 6 Key Developments

12.5 Pfizer Inc

12.5. 1 Key Facts

12.5. 2 Business Description

12.5. 3 Products and Services

12.5. 4 Financial Overview

12.5. 5 SWOT Analysis

12.5. 6 Key Developments

12.6 AstraZeneca Plc

12.6. 1 Key Facts

12.6. 2 Business Description

12.6. 3 Products and Services

12.6. 4 Financial Overview

12.6. 5 SWOT Analysis

12.6. 6 Key Developments

12.7 Merck KGaA

12.7. 1 Key Facts

12.7. 2 Business Description

12.7. 3 Products and Services

12.7. 4 Financial Overview

12.7. 5 SWOT Analysis

12.7. 6 Key Developments

12.8 Novartis AG

12.8. 1 Key Facts

12.8. 2 Business Description

12.8. 3 Products and Services

12.8. 4 Financial Overview

12.8. 5 SWOT Analysis

12.8. 6 Key Developments

12.9 Astellas Pharma Inc

12.9. 1 Key Facts

12.9. 2 Business Description

12.9. 3 Products and Services

12.9. 4 Financial Overview

12.9. 5 SWOT Analysis

12.9. 6 Key Developments

12.10 Eli Lilly and Co

12.10. 1 Key Facts

12.10. 2 Business Description

12.10. 3 Products and Services

12.10. 4 Financial Overview

12.10. 5 SWOT Analysis

12.10. 6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

언급된 주요 기업들

TABLE OF COMPANIES

1. Bristol-Myers Squibb Co

2. AbbVie Inc

3. Johnson & Johnson

4. F. Hoffmann-La Roche Ltd

5. Pfizer Inc

6. AstraZeneca Plc

7. Merck KGaA

8. Novartis AG

9. Astellas Pharma Inc

10. Eli Lilly and Co

표 목록 (Tables)

TABLE OF TABLES

Table 1. Russia Cancer Therapeutics Market Segmentation

Table 2. List of Vendors

Table 3. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)

Table 4. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)

Table 5. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types

Table 6. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types

Table 7. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications

Table 8. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications

Table 9. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel

Table 10. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel

Table 11. List of Abbreviations

그림 목록 (Figures)

TABLE OF FIGURES

Figure 1. Impact Analysis of Drivers and Restraints

Figure 2. Russia Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031

Figure 3. Heat Map Analysis by Key Players

Figure 4. Company Positioning and Concentration